Scholarlink

<p>Breast cancer metastasis remains a leading cause of mortality. Animal models have been instrumental in dissecting the complex metastatic cascade and have provided insights into tumor progression and mechanisms of dissemination to distant organs. However, significant gaps remain, particularly in the context of a highly heterogeneous disease like breast cancer. This review summarizes animal models utilized to study breast cancer metastasis, including mutagen-induced and genetically engineered mouse models, cell line-based syngeneic and xenograft models, patient-derived xenografts, as well as rat and zebrafish models. We summarize the strengths and limitations of each model in recapitulating key stages of metastasis, including the onset of metastasis, organ-specific tropism, and tumor-microenvironment interactions. Additionally, we highlight the importance of these models in preclinical drug testing and personalized therapy. By providing a comprehensive overview, this review aims to guide researchers in choosing the most suitable preclinical breast cancer animal model to effectively address metastasis-related questions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月14日

查看全文
  • Patrick Aouad,
  • Karim Halabi,
  • Berthe Hayar,
  • George Sflomos,
  • Cathrin Brisken,
  • Ciara Metcalfe,
  • Nadine Darwiche

摘要

Breast cancer metastasis remains a leading cause of mortality. Animal models have been instrumental in dissecting the complex metastatic cascade and have provided insights into tumor progression and mechanisms of dissemination to distant organs. However, significant gaps remain, particularly in the context of a highly heterogeneous disease like breast cancer. This review summarizes animal models utilized to study breast cancer metastasis, including mutagen-induced and genetically engineered mouse models, cell line-based syngeneic and xenograft models, patient-derived xenografts, as well as rat and zebrafish models. We summarize the strengths and limitations of each model in recapitulating key stages of metastasis, including the onset of metastasis, organ-specific tropism, and tumor-microenvironment interactions. Additionally, we highlight the importance of these models in preclinical drug testing and personalized therapy. By providing a comprehensive overview, this review aims to guide researchers in choosing the most suitable preclinical breast cancer animal model to effectively address metastasis-related questions.